Key Takeaways Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular ...

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Allurion Technologies (ALUR) announced topline results from the AUDACITY FDA pivotal trial evaluating the safety and efficacy of the Allurion Balloon. The AUDACITY trial is an open-label ...

Allurion Technologies (NYSE: ALUR) shares are moving higher Friday potentially after after the company announced plans to conduct a clinical study evaluating the combination of its Allurion Program ...

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI launches shopping agent Operator; Etsy, eBay tick higher.

550 subjects were randomized 1:1 to either two cycles of the Allurion Balloon 1 or a control group that received moderate intensity lifestyle therapy. Subjects in the treatment group received ...

The U.S. Patent and Trademark Office granted Patent No. 12,209,677, which pertains to advancements in Allurion's proprietary Balloon technology, particularly improving the precision of the valve ...

Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

If you can’t beat them then join them. In a bid to combat weakening financial performance, Allurion has revealed plans to initiate a clinical study evaluating its weight loss programme in ...

At 48 weeks, Allurion Balloon subjects had a greater than 50% responder rate and substantially greater weight loss than Control subjects Low rate of serious adverse events supports favorable ...